PURPOSE: To determine the prevalence of transmitted drug resistance (TDR) in antiretroviral (ARV)-naïve HIV-1-infected subjects who were screened for two clinical trials by geographic region and time. METHODS: Studies M03-613 and M05-730 screened ARV-naïve subjects in 2004 and 2005-2006, respectively. Screening drug resistance genotype assays were performed using population sequencing, and prevalence of drug resistance mutations (DRMs) was assessed at 39 amino acid positions in HIV-1 protease and reverse transcriptase (RT) and compared between geographic regions and calendar years. RESULTS: In 913 subjects, the prevalence of DRMs was higher in North America than in Western Europe, including any DRM (13.6% vs. 6.8%, p < .001), non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs (7.3% vs. 3.2%, p = .006), protease inhibitor (PI) DRMs (3.6% vs. 0.8%, p = .004), and nucleoside reverse transcriptase inhibitor (NRTI) DRMs (6.1% vs. 3.8%, p = ns). The prevalence of TDR to NNRTIs was higher compared to PIs within each region (p = .031 for North America, and p = .011 for Western Europe). Logistic regression analysis suggested a higher prevalence of DRMs in 2005-2006 compared to 2004 for NNRTIs (p = .03) and, to a lesser extent, for PIs (p = .07). CONCLUSION: TDR to NNRTIs was more frequent than to PIs in both geographic regions, increased over time, and was highest in North America.
PURPOSE: To determine the prevalence of transmitted drug resistance (TDR) in antiretroviral (ARV)-naïve HIV-1-infected subjects who were screened for two clinical trials by geographic region and time. METHODS: Studies M03-613 and M05-730 screened ARV-naïve subjects in 2004 and 2005-2006, respectively. Screening drug resistance genotype assays were performed using population sequencing, and prevalence of drug resistance mutations (DRMs) was assessed at 39 amino acid positions in HIV-1 protease and reverse transcriptase (RT) and compared between geographic regions and calendar years. RESULTS: In 913 subjects, the prevalence of DRMs was higher in North America than in Western Europe, including any DRM (13.6% vs. 6.8%, p < .001), non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs (7.3% vs. 3.2%, p = .006), protease inhibitor (PI) DRMs (3.6% vs. 0.8%, p = .004), and nucleoside reverse transcriptase inhibitor (NRTI) DRMs (6.1% vs. 3.8%, p = ns). The prevalence of TDR to NNRTIs was higher compared to PIs within each region (p = .031 for North America, and p = .011 for Western Europe). Logistic regression analysis suggested a higher prevalence of DRMs in 2005-2006 compared to 2004 for NNRTIs (p = .03) and, to a lesser extent, for PIs (p = .07). CONCLUSION: TDR to NNRTIs was more frequent than to PIs in both geographic regions, increased over time, and was highest in North America.
Authors: Lisa M Miller Jenkins; David E Ott; Ryo Hayashi; Lori V Coren; Deyun Wang; Qun Xu; Marco L Schito; John K Inman; Daniel H Appella; Ettore Appella Journal: Nat Chem Biol Date: 2010-10-17 Impact factor: 15.040
Authors: Joshua D Courter; Colleen J Teevan; Michael H Li; Jennifer E Girotto; Juan C Salazar Journal: Ther Clin Risk Manag Date: 2010-10-05 Impact factor: 2.423
Authors: Godwin E Imade; Atiene S Sagay; Beth Chaplin; Philippe Chebu; Jonah Musa; Jonathan Okpokwu; Donald J Hamel; Ishaya C Pam; Oche Agbaji; Jay Samuels; Seema Meloni; Jean-Louis Sankale; Prosper Okonkwo; Phyllis Kanki Journal: AIDS Res Hum Retroviruses Date: 2013-11-22 Impact factor: 2.205
Authors: Raph L Hamers; Rebecca Oyomopito; Cissy Kityo; Praphan Phanuphak; Margaret Siwale; Somnuek Sungkanuparph; Francesca Conradie; Nagalingeswaran Kumarasamy; Mariette E Botes; Thira Sirisanthana; Saade Abdallah; Patrick C K Li; Nicoletta Ngorima; Pacharee Kantipong; Akin Osibogun; Christopher K C Lee; Wendy S Stevens; Adeeba Kamarulzaman; Inge Derdelinckx; Yi-Ming Arthur Chen; Rob Schuurman; Michèle van Vugt; Tobias F Rinke de Wit Journal: Int J Epidemiol Date: 2010-11-10 Impact factor: 7.196
Authors: Kit N Simpson; Pamela P Pei; Jörgen Möller; Robert W Baran; Birgitta Dietz; William Woodward; Kristen Migliaccio-Walle; J Jaime Caro Journal: Pharmacoeconomics Date: 2013-05 Impact factor: 4.558
Authors: David P Sargeant; Michael W Hedden; Sandeep Deverasetty; Christy L Strong; Izua J Alaniz; Alexandria N Bartlett; Nicholas R Brandon; Steven B Brooks; Frederick A Brown; Flaviona Bufi; Monika Chakarova; Roxanne P David; Karlyn M Dobritch; Horacio P Guerra; Kelvy S Levit; Kiran R Mathew; Ray Matti; Dorothea Q Maza; Sabyasachy Mistry; Nemanja Novakovic; Austin Pomerantz; Timothy F Rafalski; Viraj Rathnayake; Noura Rezapour; Christian A Ross; Steve G Schooler; Sarah Songao; Sean L Tuggle; Helen J Wing; Sandy Yousif; Martin R Schiller Journal: PLoS One Date: 2014-03-27 Impact factor: 3.240